A semi-synthetic neolignan derivative from dihydrodieugenol B selectively affects the bioenergetic system of Leishmania infantum and inhibits cell division
Carregando...
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2019
Editora
NATURE PUBLISHING GROUP
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
AMARAL, Maiara
SOUSA, Fernanda S. de
SILVA, Thais A. Costa
TANIWAKI, Noemi N.
JOHNS, Deid Re M.
LAGO, Joao Henrique G.
ANDERSON, Edward A.
TEMPONE, Andre G.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
SCIENTIFIC REPORTS, v.9, article ID 6114, 15p, 2019
Resumo
Leishmaniasis is a neglected disease that affects more than 12 million people, with a limited therapy. Plant-derived natural products represent a useful source of anti-protozoan prototypes. In this work, four derivatives were prepared from neolignans isolated from the Brazilian plant Nectandra leucantha, and their effects against intracellular amastigotes of Leishmania (L.) infantum evaluated in vitro. IC50 values between 6 and 35 mu M were observed and in silico predictions suggested good oral bioavailability, no PAINS similarities, and ADMET risks typical of lipophilic compounds. The most selective (SI > 32) compound was chosen for lethal action and immunomodulatory studies. This compound caused a transient depolarization of the plasma membrane potential and induced an imbalance of intracellular Ca2+, possibly resulting in a mitochondrial impairment and leading to a strong depolarization of the membrane potential and decrease of ATP levels. The derivative also interfered with the cell cycle of Leishmania, inducing a programmed cell death-like mechanism and affecting DNA replication. Further immunomodulatory studies demonstrated that the compound eliminates amastigotes via an independent activation of the host cell, with decrease levels of IL-10, TNF and MCP-1. Additionally, this derivative caused no hemolytic effects in murine erythrocytes and could be considered promising for future lead studies.
Palavras-chave
Referências
- Bakowska J. C., 2011, JOVE-J VIS EXP, V51, P2
- Benaim G, 2011, TROP BIOMED, V28, P471
- Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032
- Brandonisio O, 2002, CLIN EXP MED, V2, P125, DOI 10.1007/s102380200017
- Bruns RF, 2012, J MED CHEM, V55, P9763, DOI 10.1021/jm301008n
- Chicharro C, 2001, ANTIMICROB AGENTS CH, V45, P2441, DOI 10.1128/AAC.45.9.2441-2449.2001
- Choi IS, 2013, J PERIODONTOL, V84, P545, DOI 10.1902/jop.2012.120180
- da Costa-Silva TA, 2015, J NAT PROD, V78, P653, DOI 10.1021/np500809a
- Docampo R, 2015, CELL CALCIUM, V57, P194, DOI 10.1016/j.ceca.2014.10.015
- Dolai S, 2009, EUKARYOT CELL, V8, P1721, DOI 10.1128/EC.00198-09
- DUARTE MIS, 1992, ULTRASTRUCT PATHOL, V16, P475
- Grecco SD, 2015, PHARM BIOL, V53, P133, DOI 10.3109/13880209.2014.912238
- Grecco SS, 2017, CHEM-BIOL INTERACT, V277, P55, DOI 10.1016/j.cbi.2017.08.017
- Grecco SS, 2017, PHYTOMEDICINE, V24, P62, DOI 10.1016/j.phymed.2016.11.015
- GREEN SJ, 1990, J IMMUNOL, V144, P278
- Manzano JI, 2011, ANTIMICROB AGENTS CH, V55, P1045, DOI 10.1128/AAC.01545-10
- Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x
- Jara M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180532
- Ji XY, 2019, CHEM SOC REV, V48, P1077, DOI 10.1039/c8cs00395e
- Kaczanowski S, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-44
- Kulkarni MM, 2009, J BIOL CHEM, V284, P15496, DOI 10.1074/jbc.M809079200
- Lago J. H. G., 2018, Drug discovery for leishmaniasis, P179
- Lagorce D, 2017, BIOINFORMATICS, V33, P3658, DOI 10.1093/bioinformatics/btx491
- Martins LF, 2016, J NAT PROD, V79, P2202, DOI 10.1021/acs.jnatprod.6b00256
- Morais C. G. V., 2015, BIOMED RES INT, V2015
- Morth JP, 2011, NAT REV MOL CELL BIO, V12, P60, DOI 10.1038/nrm3031
- Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200
- Neris PLN, 2013, EXP PARASITOL, V135, P307, DOI 10.1016/j.exppara.2013.07.007
- Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
- Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
- Paris C, 2004, ANTIMICROB AGENTS CH, V48, P852, DOI 10.1128/AAC.48.3.852-859.2004
- Rahman K., 2018, SCI REPORTS, V8, P1
- Rea A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002556
- Reimao JQ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002842
- Reimao JQ, 2011, EXP PARASITOL, V128, P111, DOI 10.1016/j.exppara.2011.02.021
- Luque-Ortega JR, 2010, METHODS MOL BIOL, V618, P393, DOI 10.1007/978-1-60761-594-1_25
- Menna-Barreto RFS, 2014, BIOMED RES INT, DOI 10.1155/2014/614014
- Saporito L, 2013, INT J INFECT DIS, V 17, pE572, DOI 10.1016/j.ijid.2012.12.024
- Schenone M, 2013, NAT CHEM BIOL, V9, P232, DOI [10.1038/NCHEMBIO.1199, 10.1038/nchembio.1199]
- Sen N, 2004, J BIOL CHEM, V279, P52366, DOI 10.1074/jbc.M406705200
- STAUBER LA, 1958, J PROTOZOOL, V5, P269, DOI 10.1111/j.1550-7408.1958.tb02565.x
- TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3
- Tiwari N, 2018, MINI-REV MED CHEM, V18, P26, DOI 10.2174/1389557517666170425105129
- Valencia-Pacheco G, 2014, CYTOKINE, V69, P56, DOI 10.1016/j.cyto.2014.05.016
- van Griensven J, 2012, INFECT DIS CLIN N AM, V26, P309, DOI 10.1016/j.idc.2012.03.005
- Vannier-Santos MA, 2002, CURR PHARM DESIGN, V8, P297, DOI 10.2174/1381612023396230
- Vendrametto MC, 2010, PARASITOL INT, V59, P154, DOI 10.1016/j.parint.2009.12.009
- Weischenfeldt J., 2008, COLD SPRING HARBOR P, V3
- Westrop GD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136891
- WHO, 2017, INT NEGL TROP DIS GL
- WICKRAMASINGHE SN, 1987, CLIN LAB HAEMATOL, V9, P271, DOI 10.1111/j.1365-2257.1987.tb00091.x
- Wulsten I. F., 2017, MOLECULES, V22, P1